Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2013

View Archived Issues

New results reported in murine model of spinocerebellar ataxia

Isis Pharmaceuticals presents phase I data for ISIS-PTP-1BRx

Preclinical results and initiation of first-in-human trial of ATROSAB

Preclinical evaluation of miRNA inhibitor in severe PAH

PsychoGenics and Sunovion Pharmaceuticals expand CNS partnership

Genmab and ADC Therapeutics collaborate on antibody-drug conjugate

Genocea Biosciences prepares new vaccines for HSV-2 infection

First patient dosed in phase III study of Zubsolv for new indication

Amgen presents phase I results for AMG-181 in patients with Crohn's disease and ulcerative colitis

Fluvoxamine maleate enters Japanese phase III trial for pediatric OCD

DaVita and Myriad establish protein biomarker discovery collaboration

Additive therapy with ESKM leads to complete eradication of tumors in vivo

WHO issues interim guidance on bedaquiline for pulmonary multidrug-resistant TB

New EP2 receptor antagonists patented by Bayer

Civitas Therapeutics receives second Michael J. Fox Foundation grant for CVT-301

Beta Pharma presents novel HDAC6 inhibitors

Phenex Pharmaceuticals designs new RORgamma ligands

iCo Therapeutics completes enrollment in phase II iDEAL trial

Chinese researchers patent novel alpha1A-adrenoceptor antagonists

PhaseBio expands clinical development of Vasomera for cardiopulmonary diseases

Novel PARP-1 inhibitors presented by Chengdu Di'ao Pharmaceutical Group

MEI Pharma commences phase II trial of pracinostat and Vidaza in frontline MDS

ViroMed advances in phase II trial of VM-202-DPN

FDA obtains license from GVK Biosciences for GOSTAR database

Oxygen Biotherapeutics gives update on Oxycyte

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...